特发性多中心型Castleman病的分型和治疗研究进展

张路; 李剑

doi:10.13201/j.issn.1004-2806.2025.01.006

特发性多中心型Castleman病的分型和治疗研究进展

张路¹,
李剑^1, ,

- 中国医学科学院北京协和医院血液内科(北京，100730)
基金项目:
中国医学科学院临床与转化医学研究专项(No: 2023-I2M-C&T-B-045)

详细信息

作者简介:
李剑，现任北京协和医院血液内科科室主任，主任医师，博士生导师。中华医学会血液学分会委员，北京医师协会血液科医师分会副会长，《中华血液学杂志》编委，中国Castleman病协作组组长，中国少见浆细胞病协作组组长。科研方向主要集中在浆细胞疾病及血液罕见病的临床和基础研究。相关研究成果作为通讯作者(含共同)在Circulation、Blood(2011，2019)、Leukemia(2017，2017，2019，2021，2022)等国际主流血液学期刊上发表SCI论文80余篇。

通讯作者: 李剑，E-mail：lijian@pumch.cn

中图分类号: R551.2

收稿日期: 2024-10-21

刊出日期: 2025-01-01

Research progress in the classification and treatment of idiopathic multicentric Castleman disease

ZHANG Lu¹,
LI Jian^1, ,

- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China

More Information

Corresponding author: LI Jian, E-mail: lijian@pumch.cn

Received Date: 21 October 2024

Publish Date: 01 January 2025

摘要

摘要: 特发性多中心型Castleman病(idiopathic multicentric Castleman disease，iMCD)是一种罕见血液疾病。2017年，国际Castleman病协作组(Castleman disease collaborative network，CDCN)在Blood杂志上发表了国际首个iMCD诊断共识，首次将该病分为iMCD-NOS和iMCD-TAFRO两个亚型，奠定了该病诊断和分型的基础。2018年，CDCN同样在Blood杂志上发表了全球首个iMCD治疗指南，奠定了白细胞介素-6靶向治疗在该病中的重要地位。前述共识/指南发布以来，通过国内外研究者的持续努力，对该病的分型和治疗(尤其是非白细胞介素-6为靶点的治疗)进行了新的探索。文章旨在回顾和介绍iMCD分型和治疗领域的研究进展。
- 特发性多中心型Castleman病 /
- 分型 /
- 治疗 /
- 研究进展
Abstract: Idiopathic multicentric Castleman disease(iMCD) is a rare hematological disease. In 2017, Castleman disease collaborative network(CDCN) published the first international consensus on diagnostic criteria for iMCD which further classified this disease into iMCD-NOS and iMCD-TAFRO. In 2018, CDCN published the first international evidence-based treatment guidelines for iMCD which emphasized the role of interleukin-6(IL-6) targeted therapy. Since publication of these two excellent works in Blood, researchers worldwide have been contributing in the classification and treatment(especially therapy directed against targets other than IL-6-signaling pathway) of this rare disease. This review aims to give a brief delineation of progress in the classification and treatment of iMCD since 2018.
- idiopathic multicentric Castleman disease /
- classification /
- treatment /
- research progress

HTML全文

参考文献(19)

[1]	Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease[J]. Blood, 2017, 129(12): 1646-1657. doi: 10.1182/blood-2016-10-746933
[2]	van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J]. Blood, 2018, 132(20): 2115-2124. doi: 10.1182/blood-2018-07-862334
[3]	中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(7): 529-534.
[4]	Zhang L, Dong YJ, Peng HL, et al. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria[J]. Lancet Reg Health West Pac, 2023, 34: 100720. http://dx.doi.org/10.1016/j.lanwpc.2023.100720
[5]	Zhang L, Liu QH, Zhou H, et al. Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCD[J]. Blood Adv, 2024, 8(21): 5598-5602. doi: 10.1182/bloodadvances.2024013728
[6]	Gao YH, Liu YT, Zhang MY, et al. Idiopathic multicentric Castleman disease(iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival[J]. Br J Haematol, 2024, 204(5): 1830-1837. doi: 10.1111/bjh.19334
[7]	Fajgenbaum DC, Langan RA, Japp AS, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease[J]. J Clin Invest, 2019, 129(10): 4451-4463. doi: 10.1172/JCI126091
[8]	Liu YT, Gao YH, Zhao H, et al. Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study[J]. Ann Hematol, 2024, 103(10): 4223-4230. doi: 10.1007/s00277-024-05783-z
[9]	Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood, 2019, 133(16): 1720-1728. doi: 10.1182/blood-2018-11-884577
[10]	Zhang L, Zhang MY, Cao XX, et al. A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD[J]. Leuk Lymphoma, 2022, 63(3): 618-626. doi: 10.1080/10428194.2021.1999437
[11]	Zhao H, Zhang MY, Shen KN, et al. A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD[J]. Blood, 2023, 141(21): 2654-2657. http://dx.doi.org/10.1182/blood.2023020009
[12]	Yin X, Liu Y, Zhong C, et al. Rituximab-bortezomib-dexamethasone induce high response rates in iMCD in clinical practice[J]. Br J Haematol, 2023, 203(5): 803-806. doi: 10.1111/bjh.19000
[13]	Zhang L, Gao YH, Li SY, et al. A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease[J]. Int J Hematol, 2024, 119(6): 631-637. doi: 10.1007/s12185-024-03747-7
[14]	Gao YH, Duan MH, Li J, et al. Successful treatment of relapsed idiopathic multicentric Castleman disease-idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report[J]. Br J Haematol, 2024, 205(3): 1208-1211. doi: 10.1111/bjh.19596
[15]	Gao YH, Li SY, Dang Y, et al. Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single-centre, retrospective study[J]. Br J Haematol, 2024.
[16]	Shi Y, Li J, Zhang L. Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report[J]. Ann Hematol, 2022, 101(11): 2529-2531. doi: 10.1007/s00277-022-04926-4
[17]	Lust H, Gong S, Remiker A, et al. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series[J]. Pediatr Blood Cancer, 2021, 68(10): e29261. doi: 10.1002/pbc.29261
[18]	Gao YH, Duan MH, Li J, et al. Ruxolitinib for the Treatment of Refractory Idiopathic Multicentric Castleman Disease: A Case Report[J]. Turk J Haematol, 2024, 41(1): 61-63.
[19]	Zhang L, Dong YJ, Gong XM, et al. A prospective trial of a novel recombinant humanizedanti-interleukin-6 receptor monoclonal antibody injection(VDJ001) in idiopathic multicentric Castleman disease: the preliminary results[J]. HemaSphere, 2023, 7(S3): e415148a. doi: 10.1097/01.HS9.0000971300.41514.8a